ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,037.59
      1.06%
      US Tech 100
      21,143.60
      -0.26%
      Dow Jones
      43,325.80
      0.07%
      Brent Oil
      72.88
      -0.01%
      Bitcoin
      96,264.13
      0.60%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Genelux Corporation (GNLX)

      7. Genelux Corporation (GNLX) News

      Genelux Corporation

      Genelux Corporation (GNLX)

      NASDAQ
      2.46
      0.07
      (2.93%)
      Closed December 26 4:00PM
      Delayed by 15 minutes
      2.46
      0.00
      (0.00%)
      After Hours: 6:32PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      GNLX News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 18 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 18 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 18 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 18 2024
      GNLX (2.93%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      October 22 2024
      GNLX (2.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      October 21 2024
      GNLX (2.93%)

      GNLX Discussion

      View Posts
      stocktowatch stocktowatch 2 weeks ago
      $GNLX Genelux_Corp Corporation to Participate in a Fireside Chat with H.C. Wainwright
      WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.



      https://finance.yahoo.com/news/genelux-corporation-participate-fireside-chat-120100563.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
      👍️0
      stocktowatch stocktowatch 2 weeks ago
      $GNLX November 2024 Corporate Presentation

      https://investors.genelux.com/static-files/cb26a67f-274b-49ab-84cc-de52b67c4118
      👍️0
      stocktowatch stocktowatch 2 weeks ago
      $GNLX NASDAQ Genelux 2024 Annual Stockholder Meeting


      👍️0
      TheFinalCD TheFinalCD 2 months ago
      https://finviz.com/quote.ashx?t=GNLX&ty=c&ta=1&p=d
      👍️0
      stocksrising stocksrising 2 months ago
      Any news for pop??
      Found it….sorry, just saw


      Genelux Corporation Announces
      First Patient Dosed in Phase 2
      Trial Evaluating Systemic
      Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
      GlobeNewswire
      - VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-
      doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer-
      - Trial represents second indication in the clinic for Olvi-Vec via systemic administration -
      - Interim readout expected mid-2025 -
      WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) - Genelux Corporation (GNLX. NaE) , a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.
      👍️0
      stocktowatch stocktowatch 3 months ago
      $GNLX Trending up resistance in play https://schrts.co/nQTnXUut
      👍️ 1 💥 1
      stocktowatch stocktowatch 3 months ago
      $GNLX On alert for News!? stay tuned..
      👍️0
      stocktowatch stocktowatch 3 months ago
      $GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

      https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html
      👍️0
      stocktowatch stocktowatch 4 months ago
      $GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe
      👍️0
      stocktowatch stocktowatch 4 months ago
      $GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY
      👍️0
      Monksdream Monksdream 4 months ago
      GNLX under $3
      👍️0
      stocktowatch stocktowatch 4 months ago
      Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html
      👍️0
      stocktowatch stocktowatch 4 months ago
      $GNLX Technical chart
      https://schrts.co/SjVYghqR
      👍️0
      stocktowatch stocktowatch 5 months ago
      $GNLX Website : https://genelux.com/
      👍️0
      Monksdream Monksdream 5 months ago
      GNLX under $3
      👍️0
      stocktowatch stocktowatch 5 months ago
      $GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical
      👍️0
      Monksdream Monksdream 7 months ago
      GNLX new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      GNLX new 52 lo
      👍️0
      Monksdream Monksdream 9 months ago
      GNLX new 52 lo
      👍️0
      MiamiGent MiamiGent 1 year ago
      GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
      Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

      https://stockcharts.com/h-sc/ui?s=GNLX

      Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

      The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.
      👍️0

      Your Recent History

      NASDAQ
      GNLX
      Genelux
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads